Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
1.650
-0.020 (-1.20%)
At close: Jul 30, 2025, 4:00 PM
1.570
-0.080 (-4.85%)
Pre-market: Jul 31, 2025, 8:04 AM EDT
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Camp4 Therapeutics stock have a consensus rating of "Buy" and an average price target of $16.5, which forecasts a 900.00% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $23.
Price Target: $16.50 (+900.00%)
Analyst Consensus: Buy
* Price targets were last updated on May 27, 2025.
Analyst Ratings
The average analyst rating for Camp4 Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $8 | Buy | Initiates | $8 | +384.85% | May 27, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 5, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $17 | Buy | Initiates | $17 | +930.30% | Nov 5, 2024 |
| JP Morgan | JP Morgan | Buy Initiates $23 | Buy | Initiates | $23 | +1,293.94% | Nov 5, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $18 | Buy | Initiates | $18 | +990.91% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
2.35M
from 652.00K
Increased by 260.74%
Revenue Next Year
510.00K
from 2.35M
Decreased by -78.32%
EPS This Year
-2.53
from -11.04
EPS Next Year
-2.25
from -2.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 4.2M | 2.6M | 2.6M |
| Avg | 2.4M | 510,000 | 849,997 |
| Low | 1.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 544.2% | 11.6% | 414.7% |
| Avg | 260.7% | -78.3% | 66.7% |
| Low | 65.3% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.12 | -1.39 | -1.27 |
| Avg | -2.53 | -2.25 | -1.97 |
| Low | -2.80 | -3.15 | -2.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.